Pozanicline (INN, [1] codenamed ABT-089) is a drug developed by Abbott, that has nootropic and neuroprotective effects. [2] [3] [4] Animal studies suggested it useful for the treatment of ADHD …

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride salt] is a selective neuronal nicotinic receptor (NNR) modulator with cognitive enhancing properties in animal …

In this study, ABT-089 was significantly superior to placebo on ADHD outcome at 40 mg given once or twice daily and was generally well tolerated (submitted). Given these positive findings …

Pozanicline (ABT-089) selectively activate neuronal nicotinic acetylcholine receptor subtypes, is a novel cholinergic agent that is a partial agonist at α4β2* nAChRs (K i =16 nM) and shows high …

Objective: ABT-089, an α4β2 neuronal nicotinic receptor partial agonist (generic name pozanicline), has demonstrated efficacy in adults with attention-deficit/hyperactivity disorder …

ABT-089 is a pioneer nAChR agonist found to enhance cognitive function with an exceptionally low incidence of adverse effects. To further investigate the mechanism of action of ABT-089, …

2009年10月1日 · Among α4β2*-nAChR, ABT-089 had partial agonist activity (7–23% of nicotine) and high selectivity for α4α5β2 nAChR as evidenced by loss of activity in thalamus of α5 −/− …

In this phase 2 crossover study, the NNR partial agonist ABT-089, at doses of 40 mg QD and 40 mg BID, was efficacious and generally well tolerated in treatment of adults with ADHD.

Background: This pilot study was designed to evaluate ABT-089, a neuronal nicotinic receptor partial agonist, as treatment for adult attention-deficit/hyperactivity disorder (ADHD). Methods: …

2011年1月1日 · To assess the safety and efficacy of ABT-089, a novel α 4 β 2 neuronal nicotinic receptor partial agonist, vs. placebo in children with attention-deficit/hyperactivity disorder …